Page last updated: 2024-09-03

gefitinib and saracatinib

gefitinib has been researched along with saracatinib in 9 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(saracatinib)
Trials
(saracatinib)
Recent Studies (post-2010) (saracatinib)
5,2315662,91919425157

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)saracatinib (IC50)
Chain A, Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.0027
Tyrosine-protein kinase ABL1Homo sapiens (human)0.03
Epidermal growth factor receptorHomo sapiens (human)1.9615
Tyrosine-protein kinase LckHomo sapiens (human)0.004
Tyrosine-protein kinase YesHomo sapiens (human)0.0038
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.2
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.0093
Platelet-derived growth factor receptor alphaHomo sapiens (human)10
Cyclin-dependent kinase 2Homo sapiens (human)10
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.0027
Tyrosine-protein kinase CSKHomo sapiens (human)0.84
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)5.209

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's6 (66.67)24.3611
2020's2 (22.22)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Das, D; Hong, J1
Asquith, CRM; Drewry, DH; East, MP; Havener, TM; Johnson, GL; Laitinen, T; Morris, DC; Naegeli, KM; Wells, CI; Zuercher, WJ1
Bharate, SB; Raghuvanshi, R1
Caballero, E; García-Cárceles, J; Gil, C; Martínez, A1
Andersen, P; Poulsen, HS; Stockhausen, MT; Villingshøj, M1
Knecht, R; Kurzweg, T; Laban, S; Möckelmann, N1
Ambudkar, SV; Chen, XG; Chen, ZS; Fu, LW; He, JH; Liang, YJ; Liu, KJ; Sim, HM; Singh, S; Sodani, K; Su, XD; Talele, TT; Wang, F; Wu, HY; Xie, JD1

Reviews

3 review(s) available for gefitinib and saracatinib

ArticleYear
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
    European journal of medicinal chemistry, 2019, May-15, Volume: 170

    Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines

2019
Kinase Inhibitors as Underexplored Antiviral Agents.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses

2022
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2012, Volume: 269, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Dasatinib; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Recurrence, Local; Palliative Care; Pyrimidines; Pyrroles; Quinazolines; Quinazolinones; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Sunitinib; Thiazoles

2012

Other Studies

6 other study(ies) available for gefitinib and saracatinib

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
    Journal of medicinal chemistry, 2019, 05-09, Volume: 62, Issue:9

    Topics: Aminoquinolines; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chordoma; Drug Design; ErbB Receptors; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines

2019
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022
Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells.
    Cancer investigation, 2009, Volume: 27, Issue:2

    Topics: Benzodioxoles; Cell Line, Tumor; Cell Movement; Cell Survival; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases

2009
Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo.
    International journal of cancer, 2013, Jan-01, Volume: 132, Issue:1

    Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzodioxoles; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gefitinib; HEK293 Cells; HeLa Cells; HL-60 Cells; Humans; MCF-7 Cells; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; rho-Associated Kinases

2013